Screener
AngioDynamics ANGO Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: AngioDynamics’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 3:42 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-048138
| Line item | May 31, 2026 | May 31, 2025 |
|---|---|---|
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents | $53,864 | $55,893 |
| Accounts receivable, net of allowances of $1,851 and $2,215 respectively | 48,325 | 42,890 |
| Inventories | 52,436 | 62,006 |
| Prepaid expenses and other | 8,769 | 7,535 |
| Total current assets | 163,394 | 168,324 |
| Property, plant and equipment, net | 27,097 | 32,300 |
Item 15. Exhibits, Financial Statement Schedules.
FAQ
- What is AngioDynamics's cash & equivalents?
- AngioDynamics (ANGO) reported cash & equivalents of $53.86M in Q1 2026.
- How has AngioDynamics's cash & equivalents changed year-over-year?
- AngioDynamics's cash & equivalents decreased by 3.6% year-over-year, from $55.89M to $53.86M.
- What is the long-term trend for AngioDynamics's cash & equivalents?
- Over 5 years (2021 to 2026), AngioDynamics's cash & equivalents has grown at a 2.3% compound annual growth rate (CAGR), from $48.16M to $53.86M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about AngioDynamics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude